

Theraclion: 2015 Financial agenda

Paris, FRANCE – January 7th, 2015 – THERACLION (Alternext, FR0010120402 – ALTHE), a company specializing in cutting-edge medical equipment for echotherapy, today announced its financial agenda for 2015.

Financial publications will be released before market opening. This schedule is indicative and subject to change.

✓	2014	Full-	-year	sales
---	------	-------	-------	-------

✓ 2014 Full-year results

✓ Annual Shareholders Meeting

✓ 2015 First-half results

Thursday January 29, 2015 Thursday March 19, 2015

Tuesday April 28, 2015

Thursday October 1st, 2015

About Theraclion

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on cutting-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound.

Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 23 people, 65 percent of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion's website: www.theraclion.com.

Theraclion is listed on Alternext Paris
Eligible for the PEA-PME, a tax-exempt share savings plan for SMEs
Ticker symbol: ALTHE – ISIN code: FR0010120402

Contacts:

TheraclionDavid Caumartin

oco

CEO

Phone: +33 (0)1 55 48 90 70 david.caumartin@theraclion.com

NewCap

Financial Communications & Investor Relations Emmanuel Huynh / Sophie Boulila Phone: +33 (0)1 44 71 94 91 theraclion@newcap.fr

ALIZE RP

Press relations Caroline Carmagnol / Valentine Boivin Phone: + 33 (0)1 44 54 36 63

theraclion@alizerp.com